Corporate information

Home

Ksilink opens its capital for pre-seed and seed investments.

We offer a unique opportunity to invest in our growth journey. Take a moment to review our strategic plan and discover how your support can drive meaningful impact.

Download our investor teaser

Born from the Ksilink Association, a public-private ecosystem, we are now on a bold mission to become Europe’s leading patient-based phenotypic drug discovery company.

The Ksilink Association has been created in 2015 with the mission to foster patient-based drug discovery in the heart of Europe through collaborations with a network of renowned partners from academia and biotechs. Our company, Ksilink Services SAS, has emerged from this dynamic ecosystem with a dedicated team equipped with cutting-edge expertise and state-of-the-art technology, driven by the ambition to become Europe’s leading patient-centered discovery engine for novel drug candidates.

Name: Ksilink

Legal name: Ksilink Services SAS

Form: Limited company (“SAS” stands for “Société par actions simplifiée”)

Creation: December 7, 2021

Share capital: 900,000€

Registered: in France under SIREN number 908 717 796

VAT number: FR22908717796

Headquarters: 16 rue Ankara 67000 Strasbourg, France

President: Ksilink Association, represented by Alain Beretz

CEO: Antoine de Lacombe

Information available as of 29.08.2025

Corporate information

Ksilink opens its capital for pre-seed and seed investments.

Born from the Ksilink Association, a public-private ecosystem, we are now on a bold mission to become Europe’s leading patient-based phenotypic drug discovery company.​

Born from the Ksilink Association, a public-private ecosystem, we are now on a bold mission to become Europe’s leading patient-based phenotypic drug discovery company.